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The objective of this paper is to consider several catagories of biomarkers of human pregnancy. The
design ofthe report is to discuss useful and promising markers and techniques. Research gaps, needs, and
priorities are also defined. Useful markers are mixed lymphocyte culture reactions, measures of lympho-
cytotoxic antibodies, histocompatibility (HLA) typing, and immunohematological evaluations. Promising
markers are measures of major basic protein and early pregnancy factor, as well as determinations of
trophoblast-lymphocyte cross-reactive (TLX) antigens. Promising techniques are flourescence-activated
cell-sorter analysis ofmaternal blood for fetal and extraembryonic tissues and immunotherapy with TLX
and other antigens to prevent spontaneous abortion. It is concluded that immunology has much to offer
the development of biomarkers of human pregnancy.
Introduction
Efforts tounderstandtheimmunologyofhuman preg-
nancyhavefocused onextraembryonicmembranes. The
rationale for this approach is the point of contact be-
tween maternal tissues and the conceptus is tropho-
blast. Cells ofthe inner cell mass differentiate into the
embryo, while extraembryonic components form an in-
terface with maternal blood and uterine cells (1). This
materno-trophoblastic interface exists at all anatomic
sitesin contact, includingplacenta, amniochorion, spiral
arteries, basal plate, and interstitial tissues.
Because of its location, the trophoblast is important
in potential maternal immune recognition and rejection
reactions. Its plasma membranes are unique inasmuch
as none ofthem express the polymorphic form of class
I or class II transplantation HLA (histocompatibility)
antigens; however, certain cytotrophoblast are reactive
with monoclonal antibodies thought to recognize mon-
omorphic (i.e., class I HLA framework) antigens. This
lack of transplantation antigens has led to speculation
abouttrophoblastic immunological neutrality; however,
numerous investigators have shown trophoblast mem-
branes are not immunologically inert (2).
Antibody Aspects of Trophoblast
Immunogenicity
The immunogens which signal and maintain maternal
recognition are extraembryonic structures at the ma-
terno-trophoblastic interface called trophoblast anti-
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gens (3). Evidence to support this comes from studies
of cell-mediated immunity which show certain tropho-
blast antigens (4) and some antitrophoblast antibodies
(5) can modulate allogeneic recognition reactions. Al-
though antitrophoblast antibodies have been identified
in some normal and abnormal pregnancies (6), such ac-
tivity cannot be identified in most normal pregnancy
sera. For example, the enzyme-linked immunosorbent
assay (ELISA) identifies antihuman trophoblast anti-
bodies more readily early than late in afirst pregnancy,
and more efficiently in first than in subsequent preg-
nancies (7).
There are at least four explanations why antitro-
phoblast antibodies are not identified in all pregnancy
sera: antibody combining sites may be bound by troph-
oblast antigens in immune complexes; trophoblast im-
munogens may stimulate the production ofblocking or
incomplete antibodies; auto-anti-idiotypic antibodies
within the network hypothesis ofantibody control may
disallow the demonstration of antitrophoblast immu-
nity; or inhibitors of antigen-antibody reactions or of
the manifestations thereof (such as complement fixa-
tion) could maskthe presence ofantibody. There is evi-
dence to support all of these possibilities; a brief dis-
cussion of each follows.
Immune Complexes
Immune complexes have been suggested as a factor
inthedecreasingabilityto demonstrate antitrophoblast
antibodies (8). This is supported by experiments that
show increased circulating immune complexes during
pregnancy, although these results are controversial.FAULK, COULAM, AND MCINTYRE
Studies of human pregnancy sera have revealed the
presence ofcirculating immune complexes composed of
five biochemically identifiable trophoblast-antitrophob-
last components, two of which can also be identified in
nulliparous nonpregnant female sera.
Increased quantities of trophoblast antigens have
beenreported inmaternal seraaspregnancy progresses
(1). This has been cited as further support for tropho-
blast antigen-containing immune complexes. Such com-
plexes could account for the difficulty in demonstrating
antitrophoblast immunity in some maternal sera.
Blocking or Incomplete Antibodies
Blocking and/orincomplete antibodies have longbeen
suspected as being important manifestations of immu-
nity in reproduction and cancer research. Techniques
were developed many years ago to identify antibodies
that were not serologically detectable by conventional
assays (9). These methods have been used to demon-
strate otherwise undetectable antibodies inanimalsren-
dered tolerant as neonates to allogeneic cells (10). Such
blocking or incomplete antibodies have been described
in host responses to transplants, cancers, tolerance in-
duction, and pregnancy.
Maternal antipaternal-blocking immunity appears to
be important in normal pregnancy, for such immunity
is absent in certain abnormal pregnancies (6,11). That
trophoblast may initiate blocking responses during
pregnancy is supported by experiments in mice that
showthat placental extracts presented duringthe onset
ofimmunization with an unrelated antigen promote the
production of blocking, and do not promote cytotoxic
antibodies (12). Blocking antibodies could be a cause of
the failure to consistently demonstrate antitrophoblast
immunity in maternal blood.
Auto-anti-idiotypic Antibodies
Auto-anti-idiotypic antibodiestoanti-HLAantibodies
in recipients of donor-specific tranfusions have been
found in sera of patients who lack demonstrable serol-
ogical responses to HLA, indicating that the presence
or absence of detectable antibody may be a reflection
of the amount of anti-idiotype (13). Sera from persons
alloimmunized through pregnancy, transfusion, or
transplantation can react with autologous T-lympho-
blasts primed against the immunizing donor (14).
These observations coupled with the finding that
primed T-cells display idiotypelike receptors for alloan-
tigens hasprompted anideathatT-cellreceptorsinduce
the formation of anti-idiotypic antibodies. Such auto-
anti-idiotypic antibodies to HLA are a general finding
during and after pregnancy (15). These antibodies may
help to understand why antitrophoblast antibodies can-
not be demonstrated in all maternal sera.
Inhibitors ofAntigen-Antibody Reactions
Inhibitors of antigen-antibody reactions have been
described in both complement-dependent (16) and com-
plement-independent (17) assays. Complement-depen-
dent cytotoxicity of paternal lymphocytes by maternal
antibodies to trophoblast antigens is impeded if the
serum either is heated 30 min at 56°C or absorbed with
immobilized heparin. The inhibitor can be removed by
a wash step before the addition of complement, and
cytotoxicity proceeds normally.
The inhibitor of complement-independent hemagglu-
tination reactions has been shown to bind concavalin-
A. It is activated by heating at 56°C for 30 min and is
under the control of an inhibitor-of-inhibitor, which is
present in plasma but not serum (17). The inhibitor-of-
inhibitor is heat labile, sensitive to calcium concentra-
tions, destroyed by Russell's viper venom, and absent
from the plasma ofpatients with a deficiency ofclotting
FactorV, suggestingthatthebloodclottingsystemmay
play a role in modulating maternal antibody-antigen in-
teractions within the placental bed.
Knowledge about the inhibitors and inhibitors-of-in-
hibitors ofantigen-antibody reactions is only beginning
to emerge; they could be important in some failures to
demonstrate maternal antitrophoblast antibodies, par-
ticularly if the sample is heated or if no attention has
been given to the type of anticoagulant used or to the
calcium concentration.
Useful Immunobiomarkers in
Human Pregnancy
In normal pregnancy, B-lymphocyte activation by
trophoblastantigens canbe demonstratedbytheelution
of maternal antitrophoblast antibodies from homoge-
nates of individual placentae (18). T-lymphocyte acti-
vation by trophoblast can be shown by demonstrating
that chemically defined trophoblast antigens (19) re-
versibly block T-lymphocyte responses to B-lympho-
cytes in mixed lymphocyte culture (MLC) reactions (4).
Normal maternal pregnancy plasma causes a similar
blockade of maternal T-cells to respond to paternal B-
cells in MLC reactions (20). Certain laboratory tests of
maternal immune responses to pregnancy have proven
to be clinically useful in the diagnosis and management
of high risk pregnancies. Four of these are considered
below.
Mixed Lymphocyte Culture (MLC)
Reactions
One of the best examples of cell-mediated immunity
in pregnancy is the MLC reaction. Inthisreaction, lym-
phocytes from two different individuals are mixed to-
gether and cultured under conditions that permit mea-
surement of their DNA metabolism, which is an index
ofthe intensity one cell reacts to the other. As a model
of pregnancy, the father's cells are cultured with the
mother's cells. The father's cells are sufficiently irra-
diated to disallow their ability to immunologically re-
spond, but theircapacity to stimulate the mother's lym-
phocytes is retained. This is called a one-way MLC
reaction.
120REPRODUCTIVE IMMUNOLOGY
One-way MLC reactions between a pregnant woman
and the father proceed normally in the mother's non-
pregnant or third-party serum or plasma, but are
blocked by plasma from the pregnant mother (20). The
most widely accepted explanation for this blockage of
allogeneic recognition is that it is caused by blocking
antibodies in the pregnant mother's blood. These anti-
bodies have specificities for allotypic trophoblast anti-
gens on the father's lymphocytes.
Convincing support of a role for blocking factors in
pregnancy comes from clinical investigations of unex-
plained spontaneous abortions. Many women with pri-
mary recurrent spontaneous abortions do not produce
afactor in theirblood that blocks invitro models ofcell-
mediatedimmunitybetweenlymphocytes fromthe mat-
ing partners (21). In some cases, this deficiency can be
overcome by immunizing the woman with lymphocytes
(22).
Lymphocytotoxic Antibodies
Lymphocytotoxins in pregnancy sera have been tra-
ditionally interpreted as being anti-HLA (23). This is
clearly not the case in secondary spontaneous abortion,
forcytotoxicityisremoved from serabyabsorption with
HLA-negative trophoblast or HLA-unrelated platelets
(24). Some pregnant patients produce non-HLA lym-
phocytotoxins, and results from experiments of idi-
otype-anti-idiotype immunity during pregnancy indi-
cate that broadly reactive lymphocytotoxins with TLX
specificity are not uncommon in normal pregnancy (24).
These findings are compatible with the ideathat normal
pregnancyrequires maternalimmunologicalrecognition
ofthe trophoblast antigens (3). Absent orinappropriate
recognitionresults infailed orfaultyimplantation ofthe
blastocyst (1).
There is much speculation about the nature of the
immunogen associated with normal pregnancy. Results
of animal model studies have prompted some investi-
gators to suggest that maternal recognition is depen-
dent upon incompatibility of major histocompatibility
complex (MHC)-encoded antigens (25). This is sup-
ported by the success of outbred as opposed to inbred
matings, the benefit ofallogeneic third-party leukocyte
immunizations on primary spontaneous abortion (26),
andbyresearchshowingabeneficialeffectonpregnancy
outcomeinmicewhenthefemaleismatedwithanMHC-
incompatible male (27).
Itisamatterforresearchtodeterminethequalitative
and quantitative parameters of lymphocytotoxins.
From a practical point of view, lymphocytotoxic anti-
bodies are markers ofsecondary spontaneous abortion.
Diagnostic characteristics ofthese antibodies are broad
(i.e., non-HLA) specificity; presence during nonpreg-
nancy; high titer (i.e., higher than normally found in
the same assayforanti-HLA); removalbypooledtroph-
oblast absorption; removal by absorption with paternal
platelets; and loss ofreactivity following heating or ab-
sorption with solid-phase heparin (16).
Histocompatibility (HLA) Typing
The role ofMHC antigens as predictors ofsuccessful
pregnancyoutcomehasbeencontroversial(28). Reports
have supported (29,30) and refuted (31,32) an associa-
tion between HLA and reproductive performance. The
variationinresultscanbeexplained bythesmallsample
sizes and the lack of homogeneity of the populations
investigated. ControversyinvolvingassociationofHLA
andreproductiveperformancecanbeexplainedbyprop-
erly classifying recurrent spontaneous aborters and
unexplained infertility.
Infertility is classified as primary or secondary. Pri-
mary infertility designates those couples who never
have conceived, and secondary infertility designates
couples who have conceived but have failed to deliver
during one or more years of unprotected intercourse
(33). Primary infertiles have a lower theoretical prob-
ability of producing heterozygote offspring, and sec-
ondary infertiles have more HLA-B antigen homozy-
gosity (34). Primary aborters have more HLA sharing
between spouses than do either secondary aborters or
childbearingcontrols (26). HLAtypingis acommonand
widely available test, and can be used as a reliable lab-
oratory procedure to assist in the differential diagnosis
of spontaneous abortion.
Immunity, Clotting, and Pregnancy
Wastage
Spontaneous abortion is common in patients with cer-
tain autoimmune diseases (35). Lupus patients canhave
lymphocytotoxins (36), lupus anticoagulants (37), or an-
ticardiolipin antibodies (38), all ofwhich are associated
with pregnancy wastage (39). These antibodies may in-
terrupt pregnancies because some of them react with
trophoblast antigens (40). Lupus anticoagulant and an-
ticardiolipin are antiphospholipid antibodies that react
with platelets and endothelium with the net effect of
prolonging laboratory measures of clotting time and
promoting in vivo thrombosis (41) (Fig. 1).
The most widely used clinical test to measure anti-
bodies that interfere with blood clottingis the activated
partial thromboplastin time (42). In the future this will
bereplacedbymore directimmunoassaysforantibodies
to phospholipids (43). Indeed, antibodies to cardiolipin
are usually measured by immunoassay (44). It has been
proposed that lupus anticoagulant and anticardiolipin
may be the same or closely related antibodies (45). The
identification ofeither or both antibodies in a sample of
blood from a pregnant woman should signal a suspicion
that the patient is at high risk oflosing her pregnancy.
Promising Immunobiomarkers in
Human Pregnancy
This section includes results ofresearch on the mea-
surement ofmaternal major basic protein (MBP) in the
diagnosis of labor before clinical labor begins, the de-
tection of early pregnancy factor (EPF) to determine
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FIGURE 1. Antibodies tophospholipid components ofplateletfactor-
3(PF3) caninterferewithassemblyofprothrombinaseandprolong
in vitro measures of clotting time, such as the aPTT. These and
other antiphospholipids, such as anticardiolipin, are thought to
promote thrombosis by inhibition of prostacycline release from
endothelium and release of thromboxane from platelets.
fertilization before implantation, and the immunobiol-
ogical and immunopathological importance of tropho-
blast-lymphocyte cross-reactive (TLX) antigens in the
assessment ofhigh-risk pregnancies.
Major Basic Protein (MBP)
MBP forms the core of the eosinophil granule and
accounts for most ofthe granule protein (46). It causes
histamine release from mast cells and basophils (47),
interacts with coagulation factors (48), and alters
smooth muscle contractility (49). In human pregnancy,
MBPincreasesinperipheralbloodindependentofeither
eosinophils or other eosinophil proteins (50), and has
been shown by using immunohistological techniques to
be localized in extravillous trophoblast (51). Pregnancy-
associated MBP has been purified from human placen-
tae. It is a strongly basic protein (pI > 11) with a mo-
lecular weight of 14,000 and is biochemically indistin-
guishable from eosinophil granule MBP.
MBP blood levels rise by 6 weeks of gestation and
return to normal by 6 weeks postpartum (50) (Fig. 2).
Quantitative studies indicate MBP levels plateau by 20
weeks of gestation at values more than 10 times the
nonpregnant state, and they rise sharply in the third
trimesterin womenwhoexperience aspontaneousonset
oflabor. This late increase accounts for 40% ofthe total
increase of MBP, and the increase begins at least 3
weeks prior to the onset of labor. Women who experi-
ence preterm labor have a similar increase (Fig. 3);
those with oxytocin-induced labor do not, nor do those
with prolonged gestation. These observations suggest
that increased MBP values are markers for the onset
of term or preterm labor.
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FIGURE 2. Plasma major basic protein (MBP) levels in one woman
during pregnancy. From Wasmoen et al. (72).
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FIGURE 3. Serum major basic protein (MBP) concentrations in
women with spontaneous terrm and pretern labor. (A) MBP levels
in six women with tenn labor; (@) MBP levels in a woman with
spontaneous onset of preterm labor; (U) MBP levels in a woman
withspontaneousruptureofmembranesfollowedbypreterm labor
and delivery at 34 weeks of gestation. From Coulam et al. (73).
Early Pregnancy Factor (EPF)
EPF is an immunosuppressive molecule, which is
measured by its capacity to enhance the ability of an-
tilymphocyte antibodies to inhibit active spontaneous
rosette formation between lymphocytes and red cells
(52). EPF is produced first by the mother within 24 hr
of fertilization and wanes in midpregnancy, by which
time its function isreplacedby an embryonic (placental)
form ofEPF. Maternal and embryonic EPF seem to be
indistinguishable. Both depend on the presence of a vi-
able embryo. In the mother, the molecule is assembled
from an oviduct component (EPA-A) and an ovarian
component (EPA-B), which is synthesized under the
so
A
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influence of a pituitary factor (prolactin) and an ovum
factor (53) (Fig. 4).
The molecule has attracted attention because it ap-
pears so early in maternalblood followingimplantation.
It seems also to be detectable in urine (Halle Morton,
personal communication, 1987). This has the practical
effect of providing a method of distinguishing truly in-
fertile couples from women who are becomingpregnant
but aborting very early. EPF is reported to be present
only during pregnancy when there is a viable embryo,
and as such it could be used as an early marker ofem-
bryonic viability. Another point of clinical interest is
that its detection in anonpregnant patient suggests the
presence of a tumor ofgerm cell origin (54).
Trophoblast-Lymphocyte Cross-Reactive
(TLX) Antigens
Studies of large number of HLA-characterized lym-
phocytes with individual TLX antisera have established
TLX antigens as being alloantigens (55). These inves-
tigations also have provided serological data that TLX
antibodies do not detect HLA or ABO antigens. Sta-
tistical analyses ofdata from studies done with the use
ofrabbit antitrophoblast antobodies suggest there are
three TLXgroupings (termed TLX-1, TLX-2 and TLX-
3) (56), and studies with T- and B-cell preparations in-
dicate the allotypes are restricted to T-cells (57).
TLX antigens have been demonstrated in seminal
plasmabycytotoxicity assays andbyusingELISAwith
rabbit and/or human antibodies on seminal plasma-
coated microtiter plates (24). These antibodies have
been used to identify TLX allotypy within seminal
plasma. Ultracentrifugation of sperm-free seminal
plasma removes TLX reactivity, as though the antigen
is present on a particulate structure like a cell mem-
brane. This may be required for antigen presentation
and recognition by the female recipient. Maternal rec-
ognition of TLX antigens in seminal plasma (Fig. 5) is
thought to signal maternal recognition and immunolog-
ical protection ofthe blastocyst (58).
Patients with recurrent secondary spontaneous abor-
tions have had one or more viable pregnancies or in-
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FIGURE 4. Assemblyofearlypregnancyfactor(EPF). Thepituitary
factor is prolactin.
trauterine deaths with the same mate before having
spontaneous abortions. Tissue typing of father and
mother usually reveals no HLA antigen sharing. These
women have high-titered, persistent antipaternal im-
munity as represented by complement-dependent and
complement-independent lymphocytotoxins (59). The
maternal antibodies are broadly reactive on HLA-char-
acterized cells; they cannot be assigned individual HLA
specificities. The womens' sera also are nonspecifically
inhibitory for MLC reactions.
Secondary recurrent spontaneous aborters are not
candidatesforimmunotherapywith leukocytes. Theim-
munological basis forthis isthat secondary aborters are
not TLX-compatible with their mates, and they appear
to respond inappropriately to theirmates' TLX seminal
plasma antigens, inasmuch as they do not mount ap-
propriate anti-idiotypic responses (Fig. 6). Some sec-
ondary spontaneous aborters have been successfully
treated with heparin injections (26). The basis for this
comes from reports that the passage of secondary
aborter sera through immunosorbent columns of solid-
phase heparin abolishes maternal antipaternal cytotox-
icity (16).
Promising Immunological
Techniques for Human Pregnancy
Molecular biology, genetics, and immunology have
discovered much common ground in the past several
years. Pregnancyresearchhasbenefited fromthesedis-
coveries, and two promising procedures will be dis-
cussed.
Fluorescence-Activated Cell-Sorting
(FACS)
Thismethodemploysfluorochrome-labeled antibodies
to identify and quantitate membrane markers on cells
in a heterogeneous mixture (60). FACS has been used
to measure the flux of fetal cells into maternal blood
during pregnancy. The technique can be employed to
isolate immunologically marked cells from a complex
mixture such as blood. FACS has been usedto measure
trophoblastmembranesinpregnantmothers'peripheral
circulation (61). The interesting thing about this ap-
proach is the possibility ofharvesting fetal cells for cy-
togenetic investigations without resorting to the more
invasive techniques ofamniocentesis or chorionic villus
biopsy.
Immunotherapy to Prevent Spontaneous
Abortion
Immunotherapy for the prevention ofprimary spon-
taneous abortions was begun in 1979 (29). Primary-
aborting women were transfused with buffy coat-en-
riched plasma from nonpaternal blood donors (22). Re-
sults thus far for more than 45 couples have shown a
successfulpregnancy rate, comparabletothatofnormal
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FIGURE 5. Control circuit in human pregnancy. (*) indicates site of defect manifest by recurrent primary spontaneous aborters, i.e., lack of
maternal recognition ofpatemal TLX antigens in seminal plasma. (**) indicates site ofdefect manifest by recurrent secondary spontaneous
aborters, i.e., maternal anti-idiotypic response to anti-TLX antibody.
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FIGURE 6. Summary ofrole of TLX antigens in normal and abnor-
mal human pregnancies.
childbearing women. No graft versus host (GvH) re-
actions have been observed in any ofthe offspring (26),
and no evidence of intrauterine growth retardation
(IUGR) has been found. Other groups have used pa-
ternal cells in immunotherapy to prevent spontaneous
abortion (30). They have observed perinatal problems
such as IUGR and GvH reactions. Another group has
conducted a controlled study with the use of paternal
lymphocytes and found no serious perinatal problems,
an absence ofGvH reactions, and results comparable to
those obtained with the use ofnonpaternal blood donors
(62).
Immunotherapy for the prevention of primary spon-
taneous abortion has slowed due tothe dangerofHTLV
III in blood. Screening for HTLV III should help to
alleviate some ofthe anxietyaboutsuchimmunotherapy
programs; meanwhile, several groups are studying the
possibilityofdevisingmethods ofTLXstimulationwith-
out using leukocytes. Techniques presently under in-
vestigation involve the use of trophoblast membranes,
seminal plasma, or platelets. Double blind studies of
trophoblast antigens in immunotherapy are currently
underway at the University of Liverpool in England,
and a controlled investigation of seminal plasma anti-
gens is being done at the Methodist Center for Repro-
duction and Transplantation Immunology in Indianap-
olis.
Research Gaps/Needs in Pregnancy
lmmunobiomarkers
Measures of Spiral Artery Function
As well as can be discovered by using immunohisto-
logicaltechniques, the endovascular cytotrophoblast se-
cretes a molecule found in amniotic epithelium that is
designated as amnion antigen-3 (AA3) (63). This ma-
terial is associated with changing spiral artery histo-
chemistry and, presumably, function (64). Inasmuch as
placental perfusion depends upon maternal blood flow
through spiral arteries, it is important to develop tech-
niques to measure spiral artery function.
Ultrasound has provided a way to determine the ef-
fectiveness of spiral artery function, but it would be
more informative to develop quantitative biochemical
measures of placental bed perfusion. None of the cur-
rently studied placental proteins have proven of value
inthis regard, but not allknown placental proteins have
been studied. The AA3 protein should be studied be-
cause it appears to be central in the allogeneic relation-
ship of maternal endothelium with extraembryonic cy-
totrophoblast (65). Other markers should also be
sought.
Developments in Immunohematology
Human placentae exist inside the uterus, but outside
the body. Maternal blood has to leave the intravascular
CONTROL
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space through the uteroplacental arteries to enter in-
tervillous spaces of the placental bed. In this circum-
stance mother's blood flows past allogeneic tissues and
re-enters the maternal circulation through the uterine
veins. This curious pattern ofmaternotrophoblastic cir-
culation during normal pregnancy is associated with
quantitative changes in clotting factors and alterations
in the fibrinolytic system (66).
Antibodies to phospholipids manifest as lupus anti-
coagulants and anticardiolipin antibodies are presently
thought of as qualitative observations, but this is due
to lack of precision in the assay systems and to lack of
biochemical definitions of the antigens involved. With
better assays and more clearly defined antigens, some
of the currently used immunohematological tests will
be useful biomarkers in normal and/or high risk preg-
nancies.
Role ofAnimal Models in Human
Pregnancy Research
Two important general messages have emerged from
research on animalmodels inreproductive immunology:
the need forgenetic diversitybetweenmatingpartners,
and the key role played by trophoblast in materno-fetal
interactions (67). Clinical studies of the reproductive
performance ofwomen with repeated pregnancy losses
and multiple partners have revealed the same two im-
portant general messages (68,69). Inlight ofthe success
of preventing primary spontaneous abortions by im-
munizinghuman mothers with the father's (62) orthird-
party(26)leukocytes, anideaarosethatpregnancywas-
tage in CBA x DBA matings in mice might be pre-
vented by a similar type of immunotherapy. Primipa-
rous, nulliparous CBA female mice immunized with
third-party leukocytes and mated to DBA/2 males do
have increased pregnancy success (70,71), and a series
of immunogenetic studies have been performed to ex-
plore the mechanisms ofimproved pregnancy outcome
following immunotherapy in these animals (25).
The favorable effect on pregnancy outcome when
CBA females are immunized with third party (C57BL)
leukocytes seems only to be obtained in the first preg-
nancy. When immunization is continued into a second
pregnancy, the females are found to have the same per-
centage offetalresorptions asunimmunized virgin CBA
females mated with DBA/2 males. If this effect is due
to MHC-encoded antigens in the immunizing cells, it is
difficult to understand why the protecting effect on the
first pregnancy is associated with a deleterious effect
on the second pregnancy.
Two lines ofevidence support an interpretation that
anti-TLX and not anti-MHC is responsible for the fa-
vorable effect in nulliparous and unfavorable effect in
multiparous mice. The first is an observation from our
laboratorythatthefetalresorptionrateinunimmunized
nulliparous mice falls to a small resorption rate in a
second pregnancy, suggesting that the mother is bio-
logically immunized to trophoblast antigens as a con-
sequence ofherfirstpregnancy. The second isthatanti-
MHC antibodies are rarely ifever associated with fetal
wastage. In contrast, antitrophoblast antibodies have
been used to cause abortion in laboratory animals, and
cytotoxic anti-TLX antibodies are a common feature of
recurrent secondary spontaneous abortion. The CBA x
DBA/2 model has provided interesting information, but
its relevance to human pregnancy has yet to be deter-
mined.
Research Priorities
The object of this paper has been to discuss several
of the currently available and promising new immuno-
biomarkers for use in reproductive and developmental
toxicology. The science oftoxicology has been and will
be used to assess the impact of certain toxins and/or
environmental pollutants on pregnancy outcome. How-
ever, as discussed throughout this paper, certain cou-
ples are at high risk for reproductive failure. The un-
witting inclusion of high risk couples in large epide-
miological studies of environmental factors on repro-
ductive performance will cloud the issue of the patho-
physiological effects of such environmental factors on
normalpatterns ofreproduction, because such high risk
couples are not rare.
It is essential to develop tests that identify, flag, tag,
or otherwise signalthe at-risk couples inanypopulation
about to come under investigation. In this regard,
rather simple immunological tests are available, and
promising procedures are being developed. It would
seem to be a first order research priority to validate or
discard existing tests and to direct support toward the
development and validation of promising techniques.
This would clear a way for research on new techniques
which evolve from new methodological and conceptual
advances in reproductive immunobiology.
REFERENCES
1. Faulk, W. P., and McIntyre, J. A. Immunological studies ofhu-
man trophoblast: markers, subsets and functions. Immunol. Rev.
75: 372-408 (1983).
2. Faulk, W. P., and Hsi, B. L. Immunobiology of human tropho-
blast membranes. In: Biology of Trophoblast (Y. W. Loke and
A. Whyte, Eds.), Elsevier, New York, 1983, pp. 535-569.
3. Faulk, W. P., and McIntyre, J. A. Trophoblast survival. Trans-
plantation 32: 1-5 (1981).
4. McIntyre, J. A., and Faulk, W. P. Trophoblast modulation of
maternal allogeneic recognition. Proc. Natl. Acad. Sci. (U.S.) 76:
4029-4032 (1979).
5. McIntyre,J. A., andFaulk, W. P. Antigensofhumantrophoblast:
effects of heterologous anti-trophoblast sera on lymphocyte re-
sponses in vitro. J. Exp. Med. 149: 824-836 (1979).
6. McIntyre, J. A., McConnachie, P. R., Taylor, C. S., and Faulk,
W. P. Clinical, immunologic and genetic definitions of primary
and secondary recurrent spontaneous abortions. Fertil. Steril.
42: 849-855 (1984).
7. Davies, M., and Browne, C. M. Anti-trophoblast antibody re-
sponses during normal human pregnancy. J. Reprod. Immunol.
7: 285-297 (1985).
8. Davies, M. Antigenic analysis of immune complexes formed in
normal human pregnancy. Clin. Exp. Immunol. 61: 406-415
(1985).
9. Gorer, P., Mikulska, Z. B., and O'Gorman, P. The time of ap-126 FAULK, COULAM, AND MCINTYRE
pearance ofisoantibodiesduringthehomograftresponsetomouse
tumors. Immunology 2: 211-218 (1959).
10. Voisin, G., Kinsky, R. G., and Duc, H. T. Immune status ofmice
tolerant of living cells. II. Continuous presence and nature of
facilitation-enhancing antibodiesintolerantanimals. J. Exp. Med.
135: 1185-1203 (1972).
11. Rocklin, R. E., Kitzmiller, J. L., and Garovoy, M. R. Maternal-
fetal relation. II. Further characterization of an immunologic
blocking factor that develops during pregnancy. Clin. Immunol.
Immunopathol. 22: 305-315 (1982).
12. Duc, H. T., Masse, A., Bobe, P., Kinsky, R. G., and Voisin, G.
A. Deviations of humoral and cellular alloimmune reactions by
placental extracts. J. Reprod. Immunol. 7: 27-39 (1985).
13. Reed, E., Hardy, M., Lattes, C., Brensilver, J., McCabe, R.,
Reemtsma, K., and Suciu-Foca, N. Anti-idiotypic antibodies and
their relevance to transplantation. Transplant. Proc. 17: 735-738
(1985).
14. Suciu-Foca, N., Reed, E., Rohowsky, C., King, P., and King,
D. W. Anti-idiotypic antibodies to anti-HLA receptors induced
by pregnancy. Proc. Natl. Acad. Sci. (U.S.) 80: 830-834 (1983).
15. Reed, E., Bonagura, V., Kung, P., King, D. W., and Suciu-Foca,
N. Anti-idiotypic antibodies to HLA-DR4 and DR2. J. Immunol.
131: 2890-2894 (1983).
16. Torry, D. S., McIntyre, J. A., Faulk, W. P., and McConnachie,
P. R. Inhibitors ofcomplement mediated cytotoxicity in normal
and secondary aborter sera. Am. J. Reprod. Immunol. Microbiol.
10: 53-57 (1986).
17. McIntyre, J. A., and Faulk, W. P. Antibody responses in sec-
ondary aborting women: effect ofinhibitors in blood. Am. J. Re-
prod. Immunol. 9: 113-118 (1985).
18. Faulk, W. P., Jeannet, M., Creighton, W. D., and Carbonara,
A. Immunological studies of human placentae. Characterization
of immunoglobulins on trophoblastic basement membranes. J.
Clin. Invest. 54: 1011-1019 (1974).
19. Faulk, W. P., Temple, A., Lovins, R., and Smith, N. Antigens
ofhumantrophoblast: aworkinghypothesis oftheirroleinnormal
andabnormalpregnancies. Proc. Natl. Acad. Sci. (U.S.) 75: 1947-
1951 (1978).
20. McIntyre, J. A., and Faulk, W. P. Maternal blocking factors in
human pregnancy are found in plasma not serum. Lancet ii: 821-
823 (1974).
21. McIntyre, J. A., and Faulk, W. P. Recurrent spontaneous abor-
tion inhumanpregnancy: results ofimmunogenetical, cellularand
humoral studies. Am. J. Reprod. Immunol. 4: 165-171 (1983).
22. Taylor, C., Faulk, W. P., and McIntyre, J. A. Prevention of
recurrent spontaneous abortions by leucocyte transfusion. J. R.
Soc. Med. 78: 623-627 (1985).
23. Konoeda, Y., Terasaki, P., Wakisaka, A., Park, M. S., and
Mickey, M. R. Public determinants of HLA indicated by preg-
nancy antibodies. Transplantation 41: 253-259 (1986).
24. Faulk, W. P., and McIntyre, J. A. Role ofanti-TLX antibody in
human pregnancy. In: Reproductive Immunology (D. A. Clark
and B. A. Croy, Eds.), Elsevier, Amsterdam, 1986, pp. 106-114.
25. Kiger, N., Chaouat, G., Kolb,J. P.,Wegmann, T. G., andGuenet,
J. L. Immunogenetic studies of spontaneous abortion in mice.
Preimmunization of females with allogeneic cells. J. Immunol.
134: 2966-2970 (1985).
26. McIntyre, J. A., Faulk, W. P., Nichols-Johnson, V. R., and Tay-
lor, C. Immunological testing and immunotherapy in recurrent
spontaneous abortion. Obstet. Gynecol. 67: 169-175 (1986).
27. Clark, D. A., Chaput, A., and Tutton, D. Active suppression of
host-vs-graft reaction in pregnant mice. VII. Spontaneous abor-
tion of allogeneic CBA/J x DBA/2 in the uterus of CBA/J mice
correlates with deficient non-T suppressor cell activity. J. Im-
munol. 136: 1668-1675 (1986).
28. Thomas, M. L., Harger, J. H., Wagener, D. K., Rabin, B. S.,
and Gill, T. J. HLAsharingand spontaneous abortion in humans.
Am. J. Obstet. Gynecol. 151: 1053-1058 (1985).
29. Taylor, C., and Faulk, W. P. Prevention of recurrent abortions
with leucocyte transfusions. Lancet 2: 68-70 (1981).
30. Beer, A. E., Quebbeman, J. F., Ayers, J. W., and Haines, R.
F. Major histocompatibility complex antigens, maternal and pa-
ternal immune responses and chronic habitual abortions in hu-
mans. Am. J. Obstet. Gynecol. 141: 987-999 (1981).
31. Mowbray, J. F., Gibbings, C. R., Sidgwick, A. S., Ruszkiewicz,
M., and Beard, R. W. Effects of transfusion in women with re-
current spontaneous abortion. Transplant. Proc. 15: 896-899
(1983).
32. Caudle, M. R., Rote, N. S., Scott, J. R., DeWitt, C., and Barney,
M. F. Histocompatibility in couples with recurrent spontaneous
abortion and normal fertility. Fertil. Steril. 39: 793-798 (1983).
33. Coulam, C. B. The diagnosis and treatment of infertility. In:
Gynecology and Obstetrics (J. Sciarra, Ed.), Harper and Row,
Hagerstown, MD, 1981, pp. 1-18.
34. Coulam, C. B., Moore, S. B., and O'Fallon, W. M. Association
between MHC antigen and reproductive performance. Am. J.
Reprod. Immunol. Microbiol. 14(2): in press.
35. Derue, G. J., Englert, H. G., and Harris, E. N. Fetal loss in
systemic lupus: association with anticardiolipin antibodies. J. Ob-
stet. Gynaecol. 5: 207-209 (1985).
36. del Junco, D. J. Association of autoimmune conditions with re-
current intrauterine death. Clin. Obstet. Gynecol. 29: 959-975
(1986).
37. Branch, D. W., Scott, J. R., Kochenour, N. K., Hershgold, E.
Obstetric complications associated with the lupus anticoagulant.
N. Engl. J. Med. 313: 1322-1326 (1985).
38. Lockshin, M. D., Druzin, M. L., Goei, S., Qumar, T., Magid, M.
Jovanovic, L., and Ferenc, M. Antibody to cardiolipin as a pre-
dictoroffetaldistress ordeathinpregnantpatientswith systemic
lupus erythematosus. N. Engl. J. Med. 3133: 152-156 (1985).
39. Garlund, B. The lupus inhibitor in thromboembolic disease and
intrauterine death in the absence of systemic lupus. Acta. Med.
Scand. 215: 293-298 (1984).
40. Bresnihan, B., Grigor, R., Oliver, M., Lewkonia, R., Lovins, R.,
Faulk, W. P., and Hughes, G. Spontaneous abortion in systemic
lupus erythematosus: an associate with trophoblast-reactive lym-
phocytotoxic antibodies. Lancet ii: 1205-1207 (1977).
41. Harris, N., Chan, J., Asherson, R., Aber, V., Gharavi, A., and
Hughes, G. Thrombosis, recurrent fetal loss and thrombocyto-
penia. Arch. Intern. Med. 146: 2153-2156 (1986).
42. Hougie, C. Circulating anticoagulants. Recent Adv. Blood Coag.
4: 63-90 (1985).
43. Branch, D. W., Rote, N. S., and Scott, J. R. The demonstration
oflupus anticoagulant by an enzyme-linked immunoadsorbant as-
say (ELISA). Chin. Immunol. Immunopathol. 39:298-303(1986).
44. Harris, E. N., Loizou, S., and Englert, H. Anticardiolipin anti-
bodies and lupus anticoagulant. Lancet 3: 1099 (1984).
45. Feinstein, D. I. Lupus anticoagulant, thrombosis, and fetal loss.
N. Engl. J. Med. 313: 1348-1350 (1985).
46. Wasmoen, T. L. Isolation and characterization of a pregnancy-
associated protein immunochemically related to the major basic
protein of eosinophils. Ph.D. thesis. The Mayo Graduate School
ofMedicine, Rochester, MN. 1986.
47. O'Donnell, M. C., Ackerman, S. J., Gleich, G. H., and Thomas,
L. L. Activation ofbasophil and mast cell histamine release by
eosinophil granule major basic protein. J. Exp. Med. 157: 1981-
1991 (1983).
48. Gleich, G. J., Loegering, D. A. Kueppers, F., Bajaj, S. P., and
Mann, K. G. Physicochemical and biological properties of the
major basic protein from guinea pig eosoniphil granules. J. Exp.
Med. 140: 313-332 (1974).
49. Vanhoutte, P., Flavahan, N. A., Slifman, N. R., and Gleich, G.
J. Eosinophil granule major basic protein causes hyperactivity of
respiratory muscle in the presence, but not the absence, of epi-
thelial cells. Proceedings of the International Union of Physio-
logical Sciences, Vancouver, Canada, 1986, p. 448 (abstract).
50. Maddox, D. E., Butterfield, J. H., Ackerman, S. J., Coulam, C.
B., and Gleich, G. L. Elevated serum levels in human pregnancy
ofamolecule immunochemically similar to eosinophilgranule ma-
jor basic protein. J. Exp. Med. 158: 1211-1226 (1983).
51. Maddox, D. E., Kephart, G. M., Coulam, C. B., Butterfield, J.
H., Benirschke, K., and Gleich, G. L. Localization of a molecule
immunochemically similar to eosinophil major basic protein in
human placenta. J. Exp. Med. 160: 29-41 (1984).
52. Rolfe, B., Cavanagh, A., Forde, C., Bastin, F., Chen, C., andREPRODUCTIVE IMMUNOLOGY 127
Morton, H. Modified rosette inhibition test with mouse lympho-
cytes for detection of EPF in human pregnancy. J. Immunol.
Methods 70: 1-11 (1984).
53. Cavanagh, A., Morton, H., Rolfe, B., and Gridley-Baird, A.
Ovum factor: a first signal of pregnancy? Am. J. Reprod. Im-
munol. Microbiol. 2: 97-101 (1982).
54. Rolfe, B., Morton, H., Cavanagh, A., and Gardiner, R. Detection
ofan early pregnancy-like substance in sera ofpatients with tes-
ticular germ cell tumors. Am. J. Reprod. Immunol. 3: 97-100
(1983).
55. McIntyre, J. A., and Faulk, W. P. Allotypic trophoblast-lym-
phocyte cross-reactive (TLX) cell surface antigens. Hum. Im-
munol. 4: 27-35 (1982).
56. McIntyre, J. A., Faulk, W. P., Verhulst, S. J., and Colliver, J.
A. Humantrophoblast-lymphocyte cross-reactive (TLX)antigens
define a new alloantigen system. Science 222: 1135-1137 (1984).
57. MacLeod, A. M., Catto, G. R. D., Steward, K. N., Mather, A.
J., Mason, R. J., Power, D. A., and McIntyre, J. A. Differential
expression of trophoblast lymphocyte cross-reactive (TLX) an-
tigens on T and B lymphocytes. Am. J. Reprod. Immunol. Mi-
crobiol. 10: 151-155 (1986).
58. Faulk, W. P., McIntyre, J. A., Kajino, T., and Torry, D. TA1
and TLX antigens in human pregnancy. In: Materno-Fetal Im-
munology (G. Chaouat, Ed.), INSERM Press, Paris, 1987, in
press.
59. McConnachie, P. R., and McIntyre, J. A. Maternal antipaternal
immunity in couples predisposed to repeated pregnancy losses.
Am. J. Reprod. Immunol. 5: 145-150 (1984).
60. Kawata, M., Parnes, J. R., and Herzenberg, L. A. Transcrip-
tional control of HLA-A,B,C, antigens in human placental cyto-
trophoblast isolated using trophoblast and HLA specific mono-
clonal antibodies and the fluorescence-activated cell sorter. J.
Exp. Med. 160: 633-651 (1984).
61. Covone, A., Mutton, D., Johnson, P. M., and Adinolfi, M. Troph-
oblast cells in peripheral blood from pregnant women. Lancet ii:
841-843 (1984).
62. Mowbray, J. F., and Underwood, J. L. Immunology ofabortion.
Clin. Exp. Immunol. 60: 1-7 (1985).
63. Hsi, B. L., Yeh, C. J. G., and Faulk, W. P. Characterization of
antibodies tohuman amnion antigens. Placenta5: 513-521 (1984).
64. Wells, M., Hsi, B. L., Yeh, C. J. G., and Faulk, W. P. Spiral
(uteroplacental) arteries of the human placental bed show the
presence ofaminiotic basement membrane antigens. Am. J. Ob-
stet. Gynecol. 150: 973-977 (1984).
65. Faulk, W. P., Hsi, B. L., McIntyre, J. A., Yeh, C. J. G., and
Muccheilli, A. Antigens of human extraembryonic membranes.
J. Reprod. Fertil. 31: 181-199 (1982).
66. Kruithof, E. K. D., Tran-Thang, C., Gudinchet, A., Hauert, J.,
Nicoloso, G., Genton, C., Welti, H., and Bachmann, F. Fibri-
nolysis in pregnancy: a study ofplasminogen activator inhibitors.
Blood 69: 460-466 (1987).
67. Rossant, J., Mauro, V. M., and Croy, B. A. Importance oftroph-
oblast genotype for survival ofinterspecific murine chimaeras. J.
Embryol. Exp. Morphol. 69: 141-149 (1982).
68. Ober, C. L., Martin, A. O., and Simpson, J. L. Shared HLA
antigens and reproductive performance among Hutterites. Am.
J. Hum. Genet. 35: 994-1004 (1983).
69. Coulam, C., McIntyre, J. A., and Faulk, W. P. Reproductive
performance in women with repeated pregnancy losses and mul-
tiple partners. Am. J. Reprod. Immunol. Microbiol. 12: 10-12
(1986).
70. Chaouat, G., Kiger, N., and Wegmann, T. Vaccination against
spontaneous abortion in mice. J. Reprod. Immunol. 5: 389-392
(1983).
71. Chaout, G., Kolb, J. P., Kiger, N. Stanislawski, M., and Weg-
mann, T. Immunologic consequences ofvaccination against abor-
tion in mice. J. Immunol. 134: 1594-1598 (1985).
72. Wasmoen, T. L., Coulam, C. B., Leiferman, K. M., and Gleich,
G. Association betweenimmunoreactive eosinophil granule major
basic protein and parturition. Proc. Natl. Acad. Sci. (U.S.), in
press.
73. Coulam, C. B., Wasmoen, T., Creasy, R., Siiteri, P., and Gleich,
G. Major basic protein as a predictor ofpreterm labor: a prelim-
inary report. Am. J. Obstet. Gynecol. 156: 790-796 (1987).